دورية أكاديمية
أعرض في EDS

MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.

التفاصيل البيبلوغرافية
العنوان: MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.
المؤلفون: Hansen LJ; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Pathology, Duke University Medical Center, Durham, North Carolina.; Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina., Sun R; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Pathology, Duke University Medical Center, Durham, North Carolina.; Scientific Research Center, China-Japan Union Hospital, Jilin University, Jilin, China., Yang R; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Pathology, Duke University Medical Center, Durham, North Carolina., Singh SX; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Pathology, Duke University Medical Center, Durham, North Carolina., Chen LH; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Pathology, Duke University Medical Center, Durham, North Carolina., Pirozzi CJ; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Pathology, Duke University Medical Center, Durham, North Carolina., Moure CJ; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Pathology, Duke University Medical Center, Durham, North Carolina., Hemphill C; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina., Carpenter AB; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina., Healy P; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina., Ruger RC; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina., Chen CJ; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina., Greer PK; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Pathology, Duke University Medical Center, Durham, North Carolina., Zhao F; Genetron Health Technologies, Inc., Research Triangle Park, North Carolina., Spasojevic I; Department of Medicine, Duke University Medical Center, Durham, North Carolina., Grenier C; Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina., Huang Z; Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina., Murphy SK; Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina., McLendon RE; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Pathology, Duke University Medical Center, Durham, North Carolina., Friedman HS; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina., Friedman AH; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina., Herndon JE 2nd; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina., Sampson JH; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina., Keir ST; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina., Bigner DD; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina., Yan H; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.; Department of Pathology, Duke University Medical Center, Durham, North Carolina., He Y; The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina. yiping.he@dm.duke.edu.; Department of Pathology, Duke University Medical Center, Durham, North Carolina.
المصدر: Cancer research [Cancer Res] 2019 Jul 01; Vol. 79 (13), pp. 3383-3394. Date of Electronic Publication: 2019 Apr 30.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE
أسماء مطبوعة: Publication: Baltimore, Md. : American Association for Cancer Research
Original Publication: Chicago [etc.]
مواضيع طبية MeSH: Gene Expression Regulation, Neoplastic*, Biomarkers, Tumor/*metabolism , Glioblastoma/*pathology , Neoplastic Stem Cells/*pathology , Purine-Nucleoside Phosphorylase/*metabolism , Purines/*metabolism, Animals ; Apoptosis ; Biomarkers, Tumor/genetics ; Cell Proliferation ; Glioblastoma/genetics ; Glioblastoma/metabolism ; Humans ; Mice ; Neoplastic Stem Cells/metabolism ; Prognosis ; Purine-Nucleoside Phosphorylase/genetics ; Survival Rate ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
مستخلص: Homozygous deletion of methylthioadenosine phosphorylase ( MTAP ) is one of the most frequent genetic alterations in glioblastoma (GBM), but its pathologic consequences remain unclear. In this study, we report that loss of MTAP results in profound epigenetic reprogramming characterized by hypomethylation of PROM1 /CD133-associated stem cell regulatory pathways. MTAP deficiency promotes glioma stem-like cell (GSC) formation with increased expression of PROM1 /CD133 and enhanced tumorigenicity of GBM cells and is associated with poor prognosis in patients with GBM. As a combined consequence of purine production deficiency in MTAP -null GBM and the critical dependence of GSCs on purines, the enriched subset of CD133 + cells in MTAP -null GBM can be effectively depleted by inhibition of de novo purine synthesis. These findings suggest that MTAP loss promotes the pathogenesis of GBM by shaping the epigenetic landscape and stemness of GBM cells while simultaneously providing a unique opportunity for GBM therapeutics. SIGNIFICANCE: This study links the frequently mutated metabolic enzyme MTAP to dysregulated epigenetics and cancer cell stemness and establishes MTAP status as a factor for consideration in characterizing GBM and developing therapeutic strategies.
(©2019 American Association for Cancer Research.)
References: Cell. 2013 Oct 10;155(2):462-77. (PMID: 24120142)
Stem Cells. 2010 Jan;28(1):5-16. (PMID: 19904829)
Cell Metab. 2012 Jul 3;16(1):9-17. (PMID: 22768835)
Cancer Sci. 2017 Feb;108(2):250-255. (PMID: 27960044)
Nature. 2012 Feb 15;483(7390):479-83. (PMID: 22343889)
Nat Neurosci. 2017 May;20(5):661-673. (PMID: 28346452)
Nature. 2006 Dec 7;444(7120):756-60. (PMID: 17051156)
Nat Rev Cancer. 2011 Sep 23;11(10):726-34. (PMID: 21941284)
Exp Cell Res. 1998 May 1;240(2):282-92. (PMID: 9597001)
J Immunol Methods. 2009 Aug 15;347(1-2):70-8. (PMID: 19567251)
Oncogene. 2017 Oct 5;36(40):5648-5657. (PMID: 28581523)
PLoS One. 2013 Jun 26;8(6):e67635. (PMID: 23840755)
Cancer Res. 1996 Dec 15;56(24):5653-8. (PMID: 8971171)
Cell Res. 2008 Oct;18(10):1037-46. (PMID: 18679414)
J Cancer. 2016 Oct 25;7(15):2179-2186. (PMID: 27994653)
Nat Rev Cancer. 2002 Jun;2(6):469-76. (PMID: 12189389)
Sci Rep. 2017 May 2;7(1):1348. (PMID: 28465555)
Nat Neurosci. 2016 Jan;19(1):10-9. (PMID: 26713744)
Nat Struct Mol Biol. 2009 Mar;16(3):304-311. (PMID: 19234465)
Exp Mol Med. 2017 Apr 28;49(4):e322. (PMID: 28450738)
Oncotarget. 2014 Nov 30;5(22):11428-41. (PMID: 25426549)
Mol Cell Proteomics. 2016 May;15(5):1498-510. (PMID: 26819315)
Cancer Res. 2009 Jul 15;69(14):5961-9. (PMID: 19567676)
Stem Cells. 2017 Apr;35(4):967-980. (PMID: 27870168)
Cancer Res. 2016 Sep 1;76(17):5143-50. (PMID: 27364552)
Clin Cancer Res. 2008 Jan 1;14(1):123-9. (PMID: 18172261)
Oncogene. 2013 Jun 27;32(26):3119-29. (PMID: 22945648)
Proc Natl Acad Sci U S A. 1981 Feb;78(2):1219-23. (PMID: 6785752)
Clin Cancer Res. 2006 Jun 15;12(12):3754-61. (PMID: 16778103)
Future Med Chem. 2012 Jul;4(11):1461-78. (PMID: 22857534)
Cancer Res. 2003 Sep 15;63(18):5821-8. (PMID: 14522905)
Cell Res. 2011 Mar;21(3):502-17. (PMID: 21321605)
J Med Chem. 2005 Jul 14;48(14):4679-89. (PMID: 16000004)
Nature. 2012 Feb 15;483(7390):484-8. (PMID: 22343896)
Cell Rep. 2016 Apr 19;15(3):574-587. (PMID: 27068473)
Science. 2016 Mar 11;351(6278):1214-8. (PMID: 26912360)
Eur J Biochem. 1980 Mar;104(2):595-602. (PMID: 7363907)
Nature. 2004 Nov 18;432(7015):396-401. (PMID: 15549107)
PLoS One. 2009 May 29;4(5):e5735. (PMID: 19478948)
Carcinogenesis. 2010 Jan;31(1):27-36. (PMID: 19752007)
Cancer Cell. 2017 Oct 9;32(4):411-426.e11. (PMID: 28966034)
Stem Cells. 2013 May;31(5):857-69. (PMID: 23307586)
Invest New Drugs. 2009 Feb;27(1):75-81. (PMID: 18618081)
Science. 2016 Mar 11;351(6278):1208-13. (PMID: 26912361)
Cell. 2016 Aug 25;166(5):1132-1146.e7. (PMID: 27565343)
Mol Med. 2011 Jan-Feb;17(1-2):103-12. (PMID: 20957337)
Cancer Cell. 2013 Jun 10;23(6):739-52. (PMID: 23707781)
Genes Dev. 2012 Jun 15;26(12):1326-38. (PMID: 22677546)
Genome Biol. 2018 Mar 27;19(1):43. (PMID: 29587824)
Cancer Res. 1991 Jun 15;51(12):3193-7. (PMID: 1904005)
Mol Cancer. 2006 Dec 02;5:67. (PMID: 17140455)
Am J Hum Genet. 2012 Apr 6;90(4):614-27. (PMID: 22464254)
BMC Med Genomics. 2009 Jun 08;2:34. (PMID: 19505326)
Nature. 2012 Feb 15;483(7390):474-8. (PMID: 22343901)
Cell. 2013 Mar 28;153(1):56-69. (PMID: 23540690)
Acta Neurol Scand. 1965;41(5):497-512. (PMID: 5867092)
Genes Dev. 2015 Jun 15;29(12):1203-17. (PMID: 26109046)
معلومات مُعتمدة: P50 CA190991 United States CA NCI NIH HHS; R35 CA197264 United States CA NCI NIH HHS; F30 CA206336 United States CA NCI NIH HHS; R01 NS101074 United States NS NINDS NIH HHS; P30 CA014236 United States CA NCI NIH HHS; T32 GM007171 United States GM NIGMS NIH HHS
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (Purines)
EC 2.4.2.1 (Purine-Nucleoside Phosphorylase)
EC 2.4.2.28 (5'-methylthioadenosine phosphorylase)
تواريخ الأحداث: Date Created: 20190502 Date Completed: 20200406 Latest Revision: 20240721
رمز التحديث: 20240721
مُعرف محوري في PubMed: PMC6810595
DOI: 10.1158/0008-5472.CAN-18-1010
PMID: 31040154
قاعدة البيانات: MEDLINE
الوصف
تدمد:1538-7445
DOI:10.1158/0008-5472.CAN-18-1010